Zacks Investment Research
22 Jun 2026, 13:55 UTC · 2h ago
Integra (IART) Shows Fast-paced Momentum But Is Still a Bargain Stock
NewsImpactScreener rates every claim in this story for market impact and maps it to the tickers most exposed.
Zacks Investment Research
22 Jun 2026, 13:55 UTC · 2h ago
NewsImpactScreener rates every claim in this story for market impact and maps it to the tickers most exposed.
What the story claims
3 claims · each scored for market impact
Integra LifeSciences (IART) has experienced significant price momentum, gaining 91.1% over the past 12 weeks. — Strong technical momentum often attracts trend-following investors and indicates positive sentiment for the specific ticker.
+0.40Integra LifeSciences (IART) has a beta of 1.24, indicating it is more volatile than the overall market. — High beta increases the risk/reward profile of the stock but does not inherently move the price.
+0.10Integra LifeSciences (IART) has a Zacks Momentum Style Score of B. — A positive analyst score provides a bullish signal but is a derivative metric rather than a fundamental catalyst.
+0.10Which stocks this story touches
Continue reading
6 related stories
Top 1 mover · tap to explore
The company is highlighted as a great investment candidate with strong price momentum and an attractive valuation.
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
How the impact breaks down
Where the story's weight lands
Stocks most exposed
Modeled from each name's sensitivity to this story
No stock impact ranking available yet.
Zacks Investment Research
2h ago
